HOME >> MEDICINE >> NEWS
ESC highlights need for screening and global risk management as statins move over the counter in UK

Today Dr John Reid, the Health Secretary for the United Kingdom (UK), announced the reclassification of statins as 'over the counter' products in the UK, to be available to members of the public directly from pharmacists without the need for a prescription. With this move, recently approved by the UK's Committee on Safety of Medicines, the UK is the first country to move a statin from prescription-only to over the counter access.

The initial statin to be available from pharmacists will be simvastatin, at a daily dosage of 10mg. Simvastatin will be targeted at individuals with a low to moderate risk of heart disease, specifically sub-populations such as men aged 50 years and over and women aged 55 and over with one or more risk factors including: obesity, cigarette smoking, insufficient physical exercise, unhealthy diet, hypertension, diabetes or family history of heart disease. An on-the-spot blood test is envisaged to assess if an individual requesting simvastatin is eligible and if the results are positive the treatment can be purchased immediately.

As a result of this decision, UK health authorities expect to increase the usage of statins in primary prevention, in order to reduce cholesterol levels in the UK population and ultimately reduce the country's high incidence of heart disease, arguing that the move is in favour of improving patient choice and access to medicines.

Statins not a stand-alone prevention measure

In light of this development, the European Society of Cardiology (ESC) stresses the importance of viewing statins appropriately within the global risk management environment.

Simvastatin, along with the other statins in its class, is a very effective treatment option in both primary and secondary cardiovascular disease prevention. However, it is by no means a substitute for lifestyle factor improvements and should only be taken in parallel to effective risk factor reduction methods such as health
'"/>

Contact: Camilla Dormer
cdormer@escardio.org
33-49-294-8627
European Society of Cardiology
12-May-2004


Page: 1 2 3

Related medicine news :

1. Other highlights in the March 16 JNCI
2. Other highlights in the March 2 JNCI
3. Other highlights in the February 2 JNCI
4. Article highlights confusion about Homeland Security safety symbols
5. Other highlights in the January 19 JNCI
6. US study highlights clear link between increased fast-food consumption and obesity
7. Other highlights in the December 15 JNCI
8. European study highlights persistent 3 decade increase in childhood cancer incidence
9. Other highlights in the December 1 JNCI
10. Ugandan study highlights best drug combinations for treating malaria in Africa
11. Study highlights importance of pesticide worker dermal exposure

Post Your Comments:
(Date:6/29/2015)... CA (PRWEB) , ... June 29, 2015 , ... ... and imprinted accessories, is offering discounted pricing on all purchases that include branding. ... foundation of a brand is the logo. The website, packaging and promotional materials, all ...
(Date:6/29/2015)... VA (PRWEB) , ... June 29, 2015 , ... ... services to government contractors, nonprofits, independent schools, and other growing businesses across the ... Insights Top 100 Value Added Resellers for the fifth consecutive year. , Based ...
(Date:6/29/2015)... ... June 29, 2015 , ... Human Factors and Usability Studies: ... 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/humanfactors , The ... to the design of new products as well as to postmarket surveillance of ...
(Date:6/29/2015)... , ... June 29, 2015 , ... People across the country give their coworkers and ... part of our culture. , But, how often do coworkers donate “life” to the ... a simple one. , “Dawna (Wright-Thompson) told me her husband was on a ...
(Date:6/29/2015)... ... June 29, 2015 , ... Two ... against C.R. Bard, Inc. and Ethicon, Inc. continue to move forward in New ... Management Conference is to be convened on Thursday, July 23rd at 12:00 p.m. ...
Breaking Medicine News(10 mins):Health News:Stock Up on Logo Branding Tools Reduced this Month and Next Month from Displays and Exhibits 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 3Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 2Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 3Health News:VA Pittsburgh Employee Donates Kidney to Coworker’s Spouse 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 3Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 4
(Date:6/29/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a developer ... is now included in the Russell 3000®, the Russell ... to the indexes occurred at the close of trading ... its comprehensive set of U.S. and global indexes. ... Cap and Global Indexes coincides with the progress we ...
(Date:6/29/2015)... , June 29, 2015  Relmada Therapeutics, ... therapies for the treatment of chronic pain, announced ... study with novel formulations of oral, enteric-coated buprenorphine ... chronic pain and opioid dependence indications has reached ... company anticipates reporting top-line results in the second ...
(Date:6/29/2015)... England , June 29, 2015  Eli ... Immunocore Limited today announced that they have entered ... the utility of Immunocore,s lead T cell receptor-based ... (LY2157299) and merestinib (LY2801653) for the treatment of ... identify combination regimens that provide synergies in efficacy ...
Breaking Medicine Technology:Trovagene Upgraded to Russell 3000, Small Cap and Global Indexes 2Trovagene Upgraded to Russell 3000, Small Cap and Global Indexes 3Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark 2Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark 3Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 2Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 3Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 4Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 5Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 6Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 7
Cached News: